BIONEER AS
Desconocido
ActiTOX: Active organotypic models for nanoparticle toxicological screening
BIONEER AS
participó en un
H2020:
H2020-MSCA-RISE-2018
Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers.
However, the traditiona...
2019-06-13 - 2024-07-31 | Financiado
2019-06-13 - 2024-07-31 | Financiado
EBiSC2: EBiSC2 A sustainable European Bank for induced pluripotent Stem Cells
BIONEER AS
participó en un
H2020:
H2020-JTI-IMI2-2017-13-two-stage
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique bank...
2019-02-28 - 2023-02-28 | Financiado
2019-02-28 - 2023-02-28 | Financiado
iP-OSTEO: Induced pluripotent stem cell seeded active osteochondral nanofibrous scaffolds
BIONEER AS
participó en un
H2020:
H2020-MSCA-RISE-2018
IP-OSTEO project focuses on development of novel cell-based scaffolds for bone and cartilage repair in patients with poor regenerative capac...
2018-11-14 - 2024-07-31 | Financiado
2018-11-14 - 2024-07-31 | Financiado
circRTrain: circular RNA Biology Training Network from biogenesis to biomarkers
BIONEER AS
participó en un
H2020:
H2020-MSCA-ITN-2016
CircRTrain focuses on circular RNAs (circRNAs), a new large class of single-stranded RNAs with covalently closed ends. CircRNAs have only ve...
2016-08-31 - 2021-09-30 | Financiado
2016-08-31 - 2021-09-30 | Financiado
TAT-CF: Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembr...
BIONEER AS
participó en un
H2020:
H2020-PHC-2014-2015
This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the d...
2015-12-01 - 2018-12-31 | Financiado
2015-12-01 - 2018-12-31 | Financiado
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems
BIONEER AS
participó en un
H2020:
H2020-MSCA-ITN-2014
Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado
2014-12-05 - 2018-12-31 | Financiado
EBISC: European Bank for induced pluripotent Stem Cells
BIONEER AS
participó en un
FP6:
EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, d...
2014-01-01 - 2017-12-31 | Financiado
2014-01-01 - 2017-12-31 | Financiado
COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets
BIONEER AS
participó en un
FP6:
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
2012-11-01 - 2017-10-31 | Financiado
2012-11-01 - 2017-10-31 | Financiado
COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets
BIONEER AS
participó en un
FP7:
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
Financiado
Financiado
CARTARDIS: Identification and validation of novel pharmaceutical drug targets for cardiovascular disease
BIONEER AS
participó en un
FP7:
"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe...
Financiado
Financiado
EURONEUT-41: EUROpean consortium on NEUTralising antibodies using gp41
BIONEER AS
participó en un
FP7:
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, pept...
Financiado
Financiado
EBISC: European Bank for induced pluripotent Stem Cells
BIONEER AS
participó en un
FP7:
EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, d...
Financiado
Financiado
RNATRAIN: The European non coding RNA network
BIONEER AS
participó en un
FP7:
Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena...
Financiado
Financiado
STEMMAD: Patient specific stem cell derived models for Alzheimer s disease and related neurodegenerative diso...
BIONEER AS
participó en un
FP7:
Future treatment of incurable neurodegenerative disorders, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), spinocerebella...
Financiado
Financiado
BEST-STEM CELLS: Biochemically Equivalent Substitutive Technology for Stem Cells
BIONEER AS
participó en un
FP7:
Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factor...
Financiado
Financiado
* No se disponen de datos de la empresa actual.